AURKA and gastrointestinal stromal tumor: AURKA overexpression has been shown to enhance the resistance of GIST cells to imatinib [21], thus an AURKA inhibitor may have potential as a therapeutic agent for both imatinib‐sensitive and imatinib‐resistant GIST [68].